Focused On-demand Library for Geranylgeranyl pyrophosphate synthase

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our top-notch dedicated system is used to design specialised libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

O95749

UPID:

GGPPS_HUMAN

Alternative names:

(2E,6E)-farnesyl diphosphate synthase; Dimethylallyltranstransferase; Farnesyl diphosphate synthase; Farnesyltranstransferase; Geranylgeranyl diphosphate synthase; Geranyltranstransferase

Alternative UPACC:

O95749; A8MVQ8; Q5T2C8; Q6NW19

Background:

Geranylgeranyl pyrophosphate synthase, known by alternative names such as farnesyl diphosphate synthase and geranyltranstransferase, plays a pivotal role in the biosynthesis of geranylgeranyl pyrophosphate. This compound is a crucial precursor for carotenoids and geranylated proteins, essential for cellular function and integrity.

Therapeutic significance:

The protein is linked to Muscular dystrophy, congenital hearing loss, and ovarian insufficiency syndrome, a disorder marked by muscle weakness, hearing loss, and ovarian insufficiency. Understanding the role of Geranylgeranyl pyrophosphate synthase could open doors to potential therapeutic strategies for this syndrome.